RxDoctor Payments Data

Gregory Spellman, MD

Pain Medicine · Savannah, GANPI 1407083207

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,592 of the $8,470 with a category attached, or 89.6%. Boston Scientific accounts for 89.2% of it on its own, with 17 other manufacturers making up the rest.

$8,470in general payments, 2019–2025

Across 344 payments — averaging $24.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$8K
  • Scilex Pharmaceuticals Inc.$143
  • Fidia Pharma USA Inc.$131
  • Nevro Corp.$118
  • Globus Medical$91
  • Biodelivery Sciences International, Inc.$85
  • plus $348 from 12 others

What the payments were for

  • Consulting fees$83310%
  • Food & beverage$7,59290%
  • Education$451%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,470 in reported general payments places this provider in the 85th percentile of 203 pain medicine providers in Georgia.

See all pain medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$258,035
Medicare patients
772
Services billed
3,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,016$21,168
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen722$20,661
ZtlidoLidocaine24$18,718
OxycontinOxycodone Hcl26$18,002
Buprenorphine69$13,459
BelbucaBuprenorphine Hcl21$11,723
Pregabalin536$9,100
Lidocaine86$7,881
MovantikNaloxegol Oxalate15$7,762
Gabapentin726$7,101
LinzessLinaclotide13$6,915
Fentanyl69$5,773
Diclofenac Sodium215$5,026
Acetaminophen-CodeineAcetaminophen With Codeine319$4,881
Tramadol Hcl699$4,655

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$143$18,71824 claims
Collegium Pharmaceutical, Inc.Belbuca$66$11,72321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 203 pain medicine providers in Georgia.

Other pain medicine in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →